Women's Health
Resources
Basic InformationLatest News
Why Quitting Smoking Might Be a Bit Tougher for WomenCleaner Air Could Mean Healthier Brains for Older WomenImmune-Based Drug Fights Advanced Endometrial Cancer: StudyBreastfeeding May Protect a Mom's Heart Years LaterAHA News: Pregnant Women Living Under Negative Social Conditions May Face Higher Heart Disease RiskFour Factors in Midlife Predict a Healthy Old Age for WomenYou Can Help Prevent Cervical CancerCOVID Vaccine May Temporarily Add 1 Day to Menstrual Cycle: StudyCould New Blood Test Predict Pregnancy Complications?Unhealthy Heart May Be Bigger Threat to Women's Brains Than Men'sNew Clues to How Ovarian Cancer Begins -- and Might Be PreventedMore U.S. Women Are Retaining Their Hearing as They AgeWhy Are More Women Using Pot, Other Cannabis Products During Pregnancy?Chemicals in Hair, Beauty Products May Interfere With Hormones During PregnancyFDA Allows Abortion Pill to Stay Available by MailDrug Combo May Fight a Tough Form of Breast CancerStress May Be Stronger Trigger for Problem Drinking in Women Than MenRemoving Ovaries During Hysterectomy Before 50 Can Bring Health RisksGastro Symptoms of Menopause May Vary by RaceBlack Women Have Triple the Odds for Lymphedema After Breast Cancer SurgeryGene Test Spots Breast Cancer Patients Who Can Skip Post-Op ChemoHPV Vaccine Is Reducing Cervical Cancers in Teens, Young WomenPostpartum Depression Can Do Long-Term Harm to Women's FinancesFDA Approves Imaging Drug That Can Help Surgeons Spot Ovarian CancersMom's Pre-Pregnancy Weight Could Affect Odds for Child's Asthma, AllergiesCould Estrogen Help Shield Women's Brains From Alzheimer's?Women Feel More Stigma From 'Spare Tire' Around Middle Than MenHPV Vaccination When Young Cuts Cervical Cancer Risk by 87%Will an Early-Stage Breast Cancer Spread? New Analysis Offers Some AnswersWomen Less Likely to Ask for More Time When Deadlines LoomWhen Climbing Corporate Ladder, Women Are as Competitive as Men: Study'Forever Chemicals' Might Raise Risk of Pregnancy ComplicationFinancial Stress Burdens More Than Half of New U.S. Moms: StudyA Faster, Cheaper Test to Gauge the Risk of Premature Delivery?Could Breastfeeding Help Women Keep Their Smarts as They Age?Stronger Breast Implant Safety Measures Announced by FDAPTSD Symptoms May Vary Throughout Menstrual Cycle: StudyVision Troubles Could Raise Midlife Depression Risk for WomenToo Little Vitamin D Could Raise Colon Cancer Risk in Black WomenWhy Are Cases of Pancreatic Cancer Rising in Young Women?Depression, Anxiety Could Raise a Pregnant Woman's Odds for C-SectionStill Too Few Women in Stroke Treatment Clinical TrialsMore Middle-Aged, Older Women Getting  'Broken Heart' SyndromeFDA Warns Against Using At-Home Dermal Filler 'Pens'AHA News: Broken Heart Syndrome Is on the Rise, Especially Among Older WomenLengthening Menstrual Cycles Near Menopause Could Predict Heart HealthPandemic Stress Altered Many Women's Menstrual CyclesBreastfeeding Longer May Lower Postpartum Depression RiskAHA News: How Black Women Can Take Control of Their Blood PressureLow-Dose Aspirin Guards Against Preeclampsia: Task Force
LinksSelf-Help Groups
Related Topics

Wellness and Personal Development
Mental Disorders

FDA Approves Imaging Drug That Can Help Surgeons Spot Ovarian Cancers

HealthDay News
by Robert Preidt
Updated: Nov 29th 2021

new article illustration

MONDAY, Nov. 29, 2021 (HealthDay News) -- Early detection of ovarian cancer helps boost a woman's survival, and the U.S. Food and Drug Administration on Monday approved a new imaging drug that can help spot tumors during surgery.

The drug, Cytalux (pafolacianine), is meant to improve a surgeon's ability to detect ovarian cancer while operating on a patient.

It is administered intravenously before surgery and is used in conjunction with a near-infrared fluorescence imaging system approved by the FDA for use with the drug.

"The FDA's approval of Cytalux can help enhance the ability of surgeons to identify deadly ovarian tumors that may otherwise go undetected," said Dr. Alex Gorovets, deputy director of the Office of Specialty Medicine in the FDA's Center for Drug Evaluation and Research.

"By supplementing current methods of detecting ovarian cancer during surgery, Cytalux offers health care professionals an additional imaging approach for patients with ovarian cancer," Gorovets added in an agency news release.

Conventional treatment for ovarian cancer includes surgery to remove as many tumors as possible, as well as chemotherapy or other targeted therapy to identify and attack specific cancer cells.

Currently, surgeons rely on preoperative imaging, visual inspection of tumors under normal light or examination by touch to identify ovarian cancer tumors.

The FDA's approval of Cytalux is based on a study of 134 women, aged 33 to 81. They received a dose of Cytalux and were evaluated under both normal and fluorescent light during surgery.

Of those women, about 27% had at least one cancerous lesion detected that was not found by standard visual or touch inspection.

The most common side effects of Cytalux included nausea, vomiting, abdominal pain, flushing, indigestion, chest discomfort, itching and hypersensitivity. Also, Cytalux may cause harm to the fetus when given to a pregnant woman, the FDA warned.

It also said that women should not take folate, folic acid or folate-containing supplements within 48 hours before administration of Cytalux.

The agency further cautioned there is a risk of false negatives and false positives with use of Cytalux. The drug — marketed by On Target Laboratories, LLC — was previously fast-tracked for approval by the FDA.

There will be more than 21,000 new cases of ovarian cancer and more than 13,000 deaths from this disease this year in the United States, according to the American Cancer Society.

More information

The American Cancer Society has more on ovarian cancer.

SOURCE: U.S. Food and Drug Administration, news release, Nov. 29, 2021




328 W. Claiborne St.
P.O. Box 964
Monroeville,
Alabama 36460
Tel: (251)575-4203
Fax:(251)575-9459


powered by centersite dot net